MaxCyte, Inc. (NASDAQ:MXCT) Position Increased by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP boosted its stake in shares of MaxCyte, Inc. (NASDAQ:MXCT - Free Report) by 15.4% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,429,071 shares of the company's stock after purchasing an additional 191,088 shares during the quarter. Dimensional Fund Advisors LP owned approximately 1.35% of MaxCyte worth $5,945,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. River Global Investors LLP boosted its holdings in shares of MaxCyte by 57.7% during the fourth quarter. River Global Investors LLP now owns 3,253,192 shares of the company's stock valued at $13,494,000 after acquiring an additional 1,190,630 shares during the period. Chevy Chase Trust Holdings LLC raised its holdings in shares of MaxCyte by 0.6% during the fourth quarter. Chevy Chase Trust Holdings LLC now owns 1,339,829 shares of the company's stock valued at $5,574,000 after buying an additional 7,781 shares during the last quarter. CenterBook Partners LP boosted its position in shares of MaxCyte by 48.2% during the fourth quarter. CenterBook Partners LP now owns 867,009 shares of the company's stock worth $3,607,000 after buying an additional 281,923 shares during the period. Royce & Associates LP increased its position in MaxCyte by 146.9% in the 4th quarter. Royce & Associates LP now owns 799,873 shares of the company's stock valued at $3,327,000 after acquiring an additional 475,949 shares during the period. Finally, Blair William & Co. IL raised its stake in MaxCyte by 3.6% during the 4th quarter. Blair William & Co. IL now owns 282,859 shares of the company's stock valued at $1,177,000 after acquiring an additional 9,900 shares in the last quarter. 68.81% of the stock is currently owned by institutional investors.

MaxCyte Stock Up 2.5%

NASDAQ MXCT traded up $0.06 on Friday, reaching $2.29. 349,872 shares of the stock traded hands, compared to its average volume of 555,372. The firm's fifty day simple moving average is $2.73 and its 200 day simple moving average is $3.58. MaxCyte, Inc. has a 12 month low of $2.10 and a 12 month high of $5.26. The company has a market cap of $242.94 million, a price-to-earnings ratio of -6.69 and a beta of 1.38.

MaxCyte (NASDAQ:MXCT - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported ($0.10) earnings per share for the quarter, meeting the consensus estimate of ($0.10). The company had revenue of $10.39 million during the quarter, compared to analyst estimates of $9.05 million. MaxCyte had a negative net margin of 78.36% and a negative return on equity of 16.00%. As a group, equities research analysts forecast that MaxCyte, Inc. will post -0.42 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on MXCT shares. Stifel Nicolaus decreased their price target on MaxCyte from $11.00 to $9.00 and set a "buy" rating for the company in a research note on Wednesday, March 12th. BTIG Research set a $6.00 target price on shares of MaxCyte and gave the company a "buy" rating in a research note on Wednesday, March 12th.

MaxCyte Company Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.